Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M

Kiniksa Pharmaceuticals International, plc

2024-Q2 EPS reported -$0.31 revenue$188,489,000

ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.
Total revenue $108.6M (Q2 2024) vs $71.5M (Q2 2023); net loss $3.9M vs net income $15.0M YoY.
2024 ARCALYST net revenue guidance increased to $405-415M from prior $370-390M.
Cash and investments $218.8M, no debt; expects to remain cash flow positive annually.
Phase 2b trial of abiprubart in Sjögren's Disease enrolling; clinical development fully funded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.